amphetamine induced mi
TRANSCRIPT
1. Myocardial Infarction: - Definition. - classification. - Signs & Symptoms. - Causes. - Risk factors. - Diagnosis. - Management.
2. Amphetamine abuse: -Common names. -Reasons for abuse -Mechanism of action -Side effects - Withdrawal Symptoms - Management of toxicity
3. Case Study: -Case scenario -Physical exam -History -Lab results -Final Diagnosis -Medications -Assessment
Definition. Mana e ent. classification.
Dia nosis.
i ns y to s.
Risk factors.
Causes.
In a myocardial infarction the heart
muscles suffer a prolonged and severe restriction of oxygenated blood. This is most commonly due to occlusion of
a coronary artery following the rupture of a vulnerable atherosclerotic plaque. The resulting ischemia if left untreated for
a sufficient period of time, can cause damage of the myocardium
1- Transmural: I v lv s t tir t ick ss f t l ft v tric lar all fr car i t icar i .
2- Subendocardial: I v lv s ltif cal ar as f cr sis t t i r 1/3 r 1/2 f t c fi l ft v tric lar all.
ST elevation MI
Normal ECG
Non ST Elevation MI
- Persistent, severe chest pain. The pain generally begins in the chest and radiates to the left arm, back neck and jaw. - Pain persists for longer than 30 min and is unrelieved by NTG. - Some patients; particularly diabetic and hypertensive s may experience abdominal pain resembling indigestion. - Other complaints: a sense of impending doom, nausea, vomiting, sweating, difficulty breathing.
Coronary artery vasospasm Ventricular hypertrophy Hypoxia Coronary artery emboli Cocaine, amphetamines, and ephedrine.
Diabetes
Tobacco smoking
Hyperlipidemia
Family history of IHD Alcohol
Hypertension
Obesity
Stress
High homocysteine levels.
Males over 45yr
Females over 55yr
Troponin. Creatine kinase. Myoglobin.
Myocardial muscle creatine kinase (CK-MB), which is found mainly in the heart . A level within the reference range does not exclude myocardial necrosis. CK-MB may not be affected by very small infarcts.
Myoglobin, a low-molecular-weight heme protein found in cardiac and skeletal muscle. Myoglobin levels are highly sensitive but not specific
Chest Radiography Echo cardiograph
Electrocardiography Complete blood count Chemistry profile C-reactive protein (CRP)Erythrocyte sedimentation rate (ESR Serum lactate dehydrogenase (LDH)
The management of STEMI and NSTEMI differ in:
STEMI:Is due to sudden thrombotic occlusion. The mainstay of treatment is thrombolytic therapy
NSTEMIIs due to an unstable plaque with aggregation of platelets. The mainstay of treatment is anti platelet drugs and anticoagulants.
1- Thrombolytic agents 2- Antithrombotic agents 3- Platelet aggregation inhibitors 4- Nitroglycerin 5- eta blockers 6- ACE inhibitors 7- Analgesics
Alteplase & Tenecteplase.
Streptokinase.
Alteplase Very short half life, so adjunctive Heparin therapy is needed. Dose: Dose: 15 mg IV bolus then 0.75 mg/kg IV over 30 min. Contraindications: stroke within last 2 months & severe uncontrolled hypertension.
Tenecteplase Dose: Give IV bolus over 5 s using body weight dosing. not to exceed 50 mg. 90 kg: 50 mg (10 mL)
Streptokinase forms a complex with plasminogen which
then converts plasminogen to plasmin. Plasmin breaks down clots as well as fibrinogen and other plasma proteins. Dose: 1.5 million U in 50 mL D5W IV over 60 min. Caution in severe hypertension.
Aspiri :
Inhibits cyclooxygenase, which produces thromboxane A2, a potent platelet activator. Dose: 160-324 mg PO .Augments activity of antithrombin III and prevents conversion of fibrinogen to fibrin. Dose: 60 U/kg (max 4000 U) IV bolus; followed by a 12 U/kg/h (max 1000 U/h) maintenance infusion. Inactivates activated factor X & factor II. Advantages include intermittent dosing and decreased requirement for monitoring. Dose: NSTEMI = 1 mg/kg SC bid STEMI= 30 mg IV single bolus plus 1 mg/kg SC
Hep ri :
Enox p rin:
ClopidogrelInhibits ADP binding to platelet receptor GP2b/3a complex, thereby inhibiting platelet aggregation.
irofib n
Abcixi
b
Chimeric humanmurine monoclonal
Antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor
antibody Binds to receptor with high affinity and reduces platelet aggregation by 80%
Dose: 75 mg PO
Dose: 0.4 g/kg/min IV for 30 min
Dose: 0.25 mcg/kg IV bolus, followed by 10 mcg/min IV for 12 h
Causes relaxation of vascular smooth muscle by stimulating
intracellular c-GMP production. Dose: 400 mcg SL
if symptoms persist, infuse IV at a rate of 5-10 mcg/min
Metoprolol
Es ololSelective beta1-adrenergic receptor blocker
Selective beta1-adrenergic receptor blocker
Dose: 5 mg IV q. 5 min TID
Loading dose: 500 g/kg/min IV over 1 min Maintenance dose: 0.1 mg/kg/min IV
These agents prevent conversion of angiotensin I to angiotensin
II, a potent vasoconstrictor, causing lowered aldosterone secretion.
Has short half-life, which makes it important drug for initiation
of ACE inhibitor therapy. Dosing: 6.25 mg PO TID ; may titrate to total 450 mg/d
May provide some preload reduction as well as reducing pain
and ensuring patient comfort.
DOC for analgesia because of reliable and predictable effects,
safety profile, and ease of reversibility with naloxone. Dose: 1-3 mg IV; repeat and titrate to pain relief.
Is suitable for patients with the clinical presentation of
STEMI within 12 h after symptom onset and with persistent ST-segment elevation. Indicated for patients in shock and those with
contraindications to thrombolytic therapy irrespective of time delay.
Facilitated PCI is defined as a pharmacological reperfusion treatment delivered prior to a planned PCI. Full-dose thrombolytic therapy Or half-dose thrombolytic therapy with a glycoprotein (GP)IIb/IIIa inhibitor.
Rescue PCI is defined as PCI performed on a coronary
artery which remains occluded despite thrombolytic therapy. Clopidogrel should be given as soon as possible to all
patients with STEMI undergoing PCI. Loading dose = 300 - 600 mg Followed by a daily dose of 75 mg.
Common names. Management of an overdose Reasons for abuse
Withdrawl Effects Side effects
Mechanism of action
A study drug
A party drug
A weight-loss drug
Increases the levels of
dopamine, serotonin, and norepinephrine in the central nervous system. The major neural systems
affected by amphetamine are largely implicated in the brain s reward circuitry.
Physical: anorexia dilated pupils hyperactivity drymouth tachycardia tachypnea hypertension acne heart attack
Psychological:
euphoria, anxiety concentration self-confidence
sociability aggression grandiosity paranoia
fatigue
mental depression excessive sleep
vivid or lucid dreams
suicidal ideation.
When oral toxicity is recent activated charcoal may be given.Benzodiazepines are the preferred initial treatment for CNS excitation, seizures, tachycardia, and hypertension.
Propofol with mechanical ventilation, may be required for severe agitation.
Hypertension that does not respond to benzodiazepines is treated with nitrates. -Blockers may be used for severe ventricular arrhythmias or tachycardia.
Case scenario Assessment Physical exam
Medications
History
Final Diagnosis
Lab results
A 32 year old Saudi man was admitted on Dec 14th 2010 through
the ER.
Co pl ining of: chest pain for more than 2 hours numbing in
nature & radiating to both shoulders & arms. Pain was aggravated by lying down & decreased by sitting.
He was discharged 4 days later on Dec 18th 2010.
Gener l Blood pressure Heart Rate Chest ECG
Conscious but in pain 190/120 mmHg 150 Beats/min Dyspnea ST elevation
Known case HTN > 2yrs
Drug addict ( 5 tablets of amphetami ne/ day )
Heavy cigarette smoker 2 packs/day
Test pCO2 pO2 Na Random Glucose LDH Trop CK
P tient re ding 6.97 3.43 130 7.3 229 0.19 329
Nor
l Range
H (4.7 6.1) Kpa L (21 26) mmol/l L (135-145)mmol/l H (3.9 6.7) mmol/l H (100 190) U/l H (0 0.1) g/l H (21-232) IU/l
Dr g name (generic)
Indication in the case
Dose 162 mg OP OD 75 mg O.P OD 40 mg O.P OD 6.25mg OP TID 8000 IU S.C 50 mg I.V TID 80 mg OD I.V 5 mg OD
Main side effect
ASA Clopidogrel Simvastatin Captopril Enoxaparin Ranitidine Tenecteplase Diazepam
Anti-platelet Anti-platelet stabilize the thrombus Antihypertensive Anti coagulant Stress ulcer Thrombolytic Amphetamine OD
Bleeding Bleeding Abdominal pain Hyperkalemia Bleeding dizziness Bleeding Sedation.
Close monitoring for development of hypotension is
recommended due to Coadministration of diazepam and captopril. Concomitant use of Captopril and Enoxaparine may
increase the risk of hyperkalemia. Serum potassium and renal function should be checked regularly.
http://www.Drugs.com http://www.merckmanuals.com/professional/sec15/ch198/ch198k.html
#sec15-ch198-ch198c-273b http://emedicine.medscape.com/article/812518-overview http://www.medicinenet.com/script/main/hp.asp